Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
about
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@ast
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@en
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@nl
type
label
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@ast
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@en
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@nl
prefLabel
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@ast
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@en
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@nl
P2860
P356
P1476
Eribulin Approval in Advanced Liposarcoma - Successful Drug or a Weaker Methodology?
@en
P2093
Sameer Rastogi
Vineet Gupta
P2860
P356
10.4103/0971-5851.203492
P577
2017-01-01T00:00:00Z